BriaCell Therapeutics Announces Pricing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,
H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the ...
Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...
The deal priced below last closing price of $5.04. ThinkEquity is acting as sole book running manager for the offering.Maximize Your ...
Check the time stamp on this data. Updated AI-Generated Signals for Briacell Therapeutics Corp. (BCTX) available here: BCTX. Type a few symbols and Take a Trial. The signals for these will appear ...
周二，H.C. Wainwright分析师Emily Bodnar将Briacell Therapeutics (NASDAQ: BCTX ...
BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback